Variable | Univariate Analysis, Odds Ratio (95% CI) | P Value | Multivariate Analysis, Odds Ratio (95% CI) | P Value |
---|---|---|---|---|
Internal medicine resident clinic | 0.28 (0.17-0.45) | <0.001 | 0.27 (0.16-0.47) | <0.001 |
Age | 1.02 (1.0-1.04) | 0.004 | ||
Female | 0.73 (0.45-1.19) | 0.216 | ||
Black/African American | 1 (0.54 - 1.84) | 0.988 | ||
Body mass index | 0.99 (0.95-1.02) | 0.683 | ||
Active tobacco use | 0.86 (0.6-1.23) | 0.419 | ||
Diagnosed hypertension | 3.43 (1.88-6.28) | <0.001 | 2.06 (1.06-3.99) | <0.001 |
Coronary artery disease | 1.6 (0.87-2.94) | 0.127 | ||
Peripheral artery disease | 0.97 (0.11-8.2) | 0.982 | ||
Cerebrovascular accident | 1.5 (0.59-3.79) | 0.391 | ||
Diabetes mellitus | 0.73 (0.42-1.25) | 0.255 | ||
Chronic kidney disease | 1.25 (0.56-2.8) | 0.575 | ||
Congestive heart failure | 1.74 (0.76-3.97) | 0.185 | ||
Atrial fibrillation | 0.93 (0.31-2.75) | 0.901 | ||
Obstructive sleep apnea | 1.76 (0.63-4.93) | 0.276 | ||
SBP | 1.17 (1.12-1.22) | <0.001 | 1.16 (1.11-1.22) | 0.031 |
DBP | 0.98 (0.95-1.02) | 0.573 | ||
Isolated SBP elevation | 1.35 (0.81-2.23) | 0.242 | ||
Isolated DBP elevation | 0.15 (0.06-0.33) | <0.001 | ||
LDL | 0.99 (0.99-1.00) | 0.351 | ||
HDL | 1.00 (0.99-1.01) | 0.589 | ||
Antihypertensive use | 2.54 (1.47-4.38) | 0.001 | ||
Thiazide | 0.83 (0.42-1.65) | 0.608 | ||
Beta-blocker | 2.33 (1.41-3.86) | 0.001 | ||
Calcium channel blocker | 1.83 (1.09-3.07) | 0.021 | ||
ACEi/ARB/ARNi | 2.32 (1.43-3.75) | 0.001 | ||
Aspirin | 1.43 (0.88-2.3) | 0.143 | ||
Statin | 1.24 (0.77-1.99) | 0.362 | ||
Established ASCVD | 1.46 (0.83-2.57) | 0.187 | ||
ASCVD 10-year risk | 1.02 (0.99-1.04) | 0.069 | ||
ASCVD ≥10% | 1.82 (0.97-3.4) | 0.059 |
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor neprilysin inhibitor; ASCVD, atherosclerotic cardiovascular disease; DBP, diastolic blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; SBP, systolic blood pressure.